You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Claims for Patent: 10,246,516

✉ Email this page to a colleague

Summary for Patent: 10,246,516

Title:	Anti-La antibodies and their use for immunotargeting
Abstract:	The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumor cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumor cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumor cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: (i) a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and (ii) a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein.
Inventor(s):	Michael Bachmann
Assignee:	Avencell Europe GmbH
Application Number:	US15/355,060

Details for Patent 10,246,516

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	August 03, 2012	⤷ Start Trial	2036-11-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,246,516

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2011287549	⤷ Start Trial
Germany	102010039018	⤷ Start Trial
European Patent Office	2600889	⤷ Start Trial
United States of America	2013216544	⤷ Start Trial
United States of America	2017158774	⤷ Start Trial
United States of America	9540446	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.